Study on the growth inhibition effect of Cetuximab combined with Paclitaxel on human breast cancer cell line MCF-7

YANG Min; ZHANG Xingping; CHENG Li; ZHOU Taoqi; RAO Mingyue

您当前的位置：

首页 >

文章列表页 >

Study on the growth inhibition effect of Cetuximab combined with Paclitaxel on human breast cancer cell line MCF-7

更新时间：2023-12-18

- Study on the growth inhibition effect of Cetuximab combined with Paclitaxel on human breast cancer cell line MCF-7
- Journal of Chongqing Medical University Vol. 37, Issue 5, Pages: 418-422(2012)
- 作者机构：
  
  重庆医科大学附属第一医院肿瘤科,重庆,400016
- 作者简介：
- 基金信息：
- DOI：
  CLC：
- Published：2012，
扫描看全文
YANG Min, ZHANG Xingping, CHENG Li, et al. Study on the growth inhibition effect of Cetuximab combined with Paclitaxel on human breast cancer cell line MCF-7. [J]. Journal of Chongqing Medical University 37(5):418-422(2012)
DOI：

YANG Min, ZHANG Xingping, CHENG Li, et al. Study on the growth inhibition effect of Cetuximab combined with Paclitaxel on human breast cancer cell line MCF-7. [J]. Journal of Chongqing Medical University 37(5):418-422(2012) DOI：

摘要

目的：观察表皮生长因子受体(Epidermal growth factor receptor

EGFR)单克隆抗体西妥昔单抗（Cetuximab）联合紫杉醇（Paclitaxel

PTX）对人乳腺癌MCF-7细胞的生长抑制作用。方法：实验分为对照组、Cetuximab组、PTX组、联合用药组。用MTT法检测Cetuximab、PTX及Cetuximab与PTX不同联合给药方案对MCF-7细胞的生长抑制率，流式细胞术检测各组细胞的凋亡率和周期分布，免疫荧光法及RT-PCR法检测PTX组和对照组细胞的EGFR蛋白及mRNA的表达。结果：MTT法检测发现PTX对MCF-7细胞的抑制作用呈剂量依赖性；Cetuximab与PTX不同的联合给药方案对MCF-7细胞的抑制强度不同，先予PTX再予Cetuximab可见明显的协同作用。与对照组相比，其余3组的细胞凋亡率均有所增加，但联合用药组较单药组更明显，差异有统计学意义（P<0.05）。与对照组比较，PTX组细胞的EGFR蛋白、mRNA的表达均减少（P<0.05）。结论：人乳腺癌MCF-7细胞对PTX敏感；PTX对MCF-7细胞的抑制作用呈剂量依赖性；Cetuximab和PTX联用可明显抑制乳腺癌MCF-7细胞的生长，促进其凋亡，二者联用具有协同作用。

Abstract

Objective: To observe the growth inhibition effect of the single clone antibody of epidermal growth factor receptor (EGFR) Cetuximab combined with Paclitaxel (PTX) on human breast cancer cell line MCF-7.Methods: The experiment involved four groups: control group

Cetuximab group

PTX group and combination group. The inhibitory rates of Cetuximab

PTX and different combinations of Cetuximab and PTX on MCF-7 cells were examined by MTT assay and the apoptosis rate and cell cycle distribution were analyzed by flow cytometry. The immunofluorescence and RT-PCR were used to evaluate the EGFR protein and mRNA expression in control group and PTX group. Results:PTX can exert inhibitory effect on MCF-7 cells in a dose dependent manner based on the results from MTT assay. MTT assay showed that different combination schemes exerted different inhibitory effects; the synergistic effect was seen in the scheme of MCF-7 cells first treated with PTX and then Cetuximab. The apoptosis rate of the other three groups was increased compared with that of control group and the effect was more evident in combination group than in single agent groups (P<0.05).The EGFR protein and mRNA expressions reduced in PTX group compared with those in control group (P<0.05).Conclusion：Human breast cancer cell line MCF-7 was sensitive to PTX and PTX can exert inhibitory effect on MCF-7 cells in a dose dependent manner. The combination of Cetuximab and PTX can increase the apoptosis and decrease the proliferation of breast cancer cell line MCF-7 with a synergistic action.

关键词

西妥昔单抗紫杉醇表皮生长因子受体乳腺癌MCF-7细胞

Keywords

cetuximabpaclitaxelepidermal growth factor receptorbreast cancerMCF-7 cell

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Inhibitory effect of low-dose paclitaxel combined with recombinant human endostatin on breast cancer MCF-7 cell line

Inhibitory effect of cetuximab combined with paclitaxel on nasopharyngeal carcinoma cell line CNE-1 and its molecular mechanism

Pathomics signature based on machine learning can predict the response to neoadjuvant chemotherapy in breast cancer patients

Effects of circular RNA hsa_circ_0002185 on cell viability and invasion of breast cancer cells and its mechanism of action

Prediction and identification of H-2Kd restricted CTL epitope derived from breast cancer associated antigen ROR1

Related Author

RAO Ming-yue

ZHANG Xing-ping

CHENG Li

ZHOU Tao-qi

YANG Min

HE Yang-ke

Liu Yang

Zhang Xingping

Related Institution

Department of Oncology,the First Affiliated Hospital,Chongqing Medical University

Department of Oncology，The First Affiliated Hospital of Chongqing Medical University

Department of Epidemiology and Health Statistics， School of Public Health，Southwest Medical University

Department of Pathology，The Affiliated Hospital of Southwest Medical University

Department of Medical Engineering Technology，School of Medical Information and Engineering，Southwest Medical University

⁰